Quarterly Report I 14/15
September 2014 – November 2014, Diamyd Medical AB (publ), Fiscal year 2014/2015Reporting period, September 1, 2014 – November 30, 2014 · Net result amounted to MSEK -5.9 (-4.8) · Result per share amounted to SEK -0.3 (-0.2) · Cash flow from operating activities amounted to MSEK -5.8 (-4.3) · Liquid assets and short term investments amountedto MSEK 29.8 (61.0) at the end of the period Significant events during the reporting period · Diamyd-licensed technology, GABA in combination with Antigen Based Therapy, cures diabetes in pre-clinical model · Diamyd®